Trastuzumab duocarmazine versus physician&#39;s choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial

Kadcyla (ado-trastuzumab emtansine) - Roche

Jivadco (trastuzumab duocarmazine) - Byondis, Medac

vinorelbine tartrate - Generic mfg.

eribulin mesylate - Generic mfg.

capecitabine - Generic mfg.

lapatinib - Generic mfg.

https://oncologypro.esmo.org/meeting-resources/esmo-congress/trastuzumab-duocarmazine-versus-physician-s-choice-therapy-in-pre-treated-her2-positive-metastatic-breast-cancer-final-results-of-the-phase-iii-tu

P.G. Aftimos1; N. Turner2; J. O'Shaughnessy3; E. van den Tweel4; M. Oesterholt4; S. Escrivá-de-Romaní5; N. Quenel Tueux6; T.J.Y. Tan7; J. Lim8; S. Ladoire9; A.C. Armstronh10; A. Stradella11; G.V. Bianchi12; M.A. Colleoni13; E. Kaczmarek14; K. Punie15; X. Song16; N. Koper4; C. Saura Manich17

Jul 27, 2023